Biotech companies by P/B ratio
Share price divided by book value per share: what the market pays for each dollar of shareholders' equity on the balance sheet.
Kodiak Sciences leads the 18 biotech companies ranked by P/B ratio, at 497, ahead of Scholar Rock Holding (34.7) and Adaptive Biotechnologies (26.2). Figures as of 18 Nov 2026, 20:14 UTC, from Yahoo Finance quotes.
Key facts
- Companies ranked
- 18
- First
- Kodiak Sciences497
- Median
- 9.0
- Combined market value
- AED 3.07T
- Countries
- 5
- Not ranked
- 6no P/B ratio on file
Market values as of .
All countries▾
All sectors▾
Biotech▾
| # | Company | P/B ↓ | Market cap | Price | Today | 1 year | Price, 30 days | Country |
|---|---|---|---|---|---|---|---|---|
| 1 | Kodiak SciencesKOD · Health Care | 497 | AED 23.4B | AED 357.70 | 0.61% up | 396% up | ||
| 2 | Scholar Rock HoldingSRRK · Health Care | 34.7 | AED 21.5B | AED 176.40 | 6.54% up | 14% up | ||
| 3 | Adaptive BiotechnologiesADPT · Health Care | 26.2 | AED 17B | AED 105.04 | 0.39% up | 88% up | ||
| 4 | AmgenAMGN · Health Care | 16.7 | AED 881.3B | AED 1,629.33 | 3.12% down | 34% up | ||
| 5 | Gilead SciencesGILD · Health Care | 16.1 | AED 769.9B | AED 620.72 | 0.74% down | 33% up | ||
| 6 | Revolution MedicinesRVMD · Health Care | 14.4 | AED 126.9B | AED 586.86 | 1.79% down | 131% up | ||
| 7 | ModernaMRNA · Health Care | 11.7 | AED 294.8B | AED 728.46 | 4.09% down | 755% up | ||
| 8 | ImmunovantIMVT · Health Care | 10.5 | AED 25.4B | AED 122.52 | 0.45% up | 43% up | ||
| 9 | ExelixisEXEL · Health Care | 9.1 | AED 61.4B | AED 251.70 | 0.04% up | 63% up | ||
| 10 | Twist BioscienceTWST · Health Care | 8.9 | AED 29.2B | AED 428.25 | 4.11% up | 340% up | ||
| 11 | CG OncologyCGON · Health Care | 7.2 | AED 26.3B | AED 294.19 | 1.47% up | 85% up | ||
| 12 | Krystal BiotechKRYS · Health Care | 6.5 | AED 34.2B | AED 1,153.19 | 5.17% up | 46% up | ||
| 13 | Kymera TherapeuticsKYMR · Health Care | 6.4 | AED 38B | AED 445.36 | 0.21% down | 87% up | ||
| 14 | Bio-TechneTECH · Health Care | 5.3 | AED 42B | AED 267.32 | 0.21% up | 26% up | ||
| 15 | RepligenRGEN · Health Care | 4.7 | AED 40.6B | AED 634.40 | 6.51% up | 5% up | ||
| 16 | Neurocrine BiosciencesNBIX · Health Care | 4.3 | AED 60.6B | AED 598.48 | 1.79% down | 20% up | ||
| 17 | VaxcytePCVX · Health Care | 3.5 | AED 34B | AED 214.90 | 1.50% down | 22% up | ||
| 18 | BiogenBIIB · Health Care | 2.0 | AED 135.7B | AED 917.94 | 0.34% down | 49% up |
Sources: share prices and market values from Yahoo Finance; sector, country and category from each company's SEC registration.
Market value is share price × shares outstanding, from Yahoo Finance; prices may be delayed 15 minutes or more and the ranking refreshes about every 20 minutes. The list covers companies with shares listed in the US, which includes foreign companies listed through ADRs but not ones listed only abroad. Sector, category and country come from each company's SEC registration. Sums are converted from US dollars at today's exchange rate (1 USD = 3.6728 AED). 6 companies have no P/B ratio on file and are not ranked here.
Questions and answers
Which biotech companies rank first by P/B ratio?
Kodiak Sciences (497), Scholar Rock Holding (34.7) and Adaptive Biotechnologies (26.2) are the top three of the 18 biotech companies ranked by P/B ratio as of 18 Nov 2026, 20:14 UTC.
How many biotech companies are in this ranking?
18 are ranked by P/B ratio. 6 more have no P/B ratio on file and are left out rather than ranked at zero.
What are these biotech companies worth together?
The 18 biotech companies ranked by P/B ratio have a combined market value of AED 3.07T as of 18 Nov 2026, 20:14 UTC.
What does ranking by P/B ratio measure?
Share price divided by book value per share: what the market pays for each dollar of shareholders' equity on the balance sheet.
Learn how this ranking works
All markets guides →- P/E ratio explained: what a high or low figure means
The price-to-earnings (P/E) ratio is a share's price divided by its earnings per share. A stock at $100 earning $5 a share has a P/E of 20: buyers pay $20 for each dollar of yearly profit. A high P/E usually means the market expects profit to grow; a low one can mean doubt, not a bargain.
- Piotroski F-score: the nine tests and what they show
The Piotroski F-score is a 0–9 count of simple accounting tests a company passes: four on profitability, three on debt, liquidity and share issuance, two on operating efficiency. Joseph Piotroski's 2000 paper found that among cheap, high book-to-market stocks, high scorers went on to beat low scorers. It is a screen of financial health, not a valuation.
- How an ETF's size is measured: AUM, NAV and creation units
An ETF's size is usually measured by its assets under management (AUM), the fund's net assets: everything it holds minus what it owes. That equals net asset value per share times shares outstanding. AUM grows when the holdings rise in value and when large institutions create new shares, and shrinks when they redeem them.
Cite this page
Funkfolio, “Biotech companies by P/B ratio”, data as of 18 November 2026. https://funkfolio.com/companies/category/biotech?by=pb-ratio
Underlying data: Yahoo Finance; SEC EDGAR.